Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Equity Ratio (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Equity Ratio for 12 consecutive years, with 0.92 as the latest value for Q1 2026.

  • For Q1 2026, Equity Ratio rose 118.34% year-over-year to 0.92; the TTM value through Mar 2026 reached 0.92, up 118.34%, while the annual FY2025 figure was 0.84, N/A changed from the prior year.
  • Equity Ratio hit 0.92 in Q1 2026 for Crescent Biopharma, up from 0.84 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q1 2026 and bottomed at 5.03 in Q1 2025.
  • Average Equity Ratio over 5 years is 0.43, with a median of 0.85 recorded in 2023.
  • On a YoY basis, Equity Ratio climbed as much as 1117.1% in 2025 and fell as far as 695.51% in 2025.
  • Crescent Biopharma's Equity Ratio stood at 0.83 in 2022, then increased by 2.31% to 0.85 in 2023, then plummeted by 109.78% to 0.08 in 2024, then surged by 1118.63% to 0.84 in 2025, then grew by 9.28% to 0.92 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.92, 0.84, and 0.84 for Q1 2026, Q4 2025, and Q3 2025 respectively.